[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100318986":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":39,"centralContacts":11,"locations":43,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":83,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"BeiGene","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: BGB-3111","EXPERIMENTAL",null,[13],"Drug: BGB-3111",{"label":15,"type":16,"description":11,"interventionNames":17},"Part A: Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",{"label":20,"type":10,"description":11,"interventionNames":21},"Part B: BGB-3111, Placebo, and Moxifloxicin",[13,18,22],"Drug: Moxifloxacin",[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","BGB-3111","Subjects will receive BGB-3111",[9,20],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Placebo","Subjects will receive Placebo",[15,20],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Moxifloxacin","Subjects will receive Moxifloxicin",[20],[38],"Avelox",[40],{"name":41,"affiliation":5,"role":42},"William Novotny, MD","STUDY_DIRECTOR",[44],{"facility":45,"status":11,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":11},"Frontage Clinical Services, Inc.","Secaucus","New Jersey","07094","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-74.05653,40.78955,{"lat":55,"lon":54},{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100318986","phase-1-a-two-part-phase-1-study-to-investigate-the-safety-and-tolerability-of-supratherapeutic-dose-of-zanubrutinib-and-effect-of-zanubrutinib-on-cardiac-repolarization-in-healthy-subjects-100318986",false,"NCT03432884","A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects","A Two-Part Study Consisting of a Randomized, Placebo-Controlled, Single Dose Safety and Tolerability Study (Part A) Evaluating a Supratherapeutic Dose of Zanubrutinib Followed by a Randomized, Placebo- and Positive-Controlled, Crossover Study (Part B) to Evaluate the Effect of Zanubrutinib on Cardiac Repolarization in Healthy Volunteers","Inclusion Criteria: All subjects\n\n1. Body mass index (BMI) 18 - 33 kg\u002Fm2, inclusive.\n2. In good general health as assessed by the Investigator.\n3. Females of non-child bearing potential.\n4. Males without a vasectomy will agree to use required barrier contraception, and will agree to not donate sperm from the time of the first dose of BGB-3111 until ≥ 90 days after the last dose of BGB-3111.\n5. Able to comprehend and willing to sign consent.\n\nExclusion Criteria: All subjects\n\n1. Subjects with a clinically relevant history or presence of any clinically significant disease.\n2. Personal or known family history of congenital or acquired long QT syndrome or cardiovascular disease.\n3. Women of child-bearing potential.\n4. History of alcoholism or drug\u002Fchemical abuse within 6 months.",true,"ALL","18 Years","55 Years",{"count":71,"type":72},40,"ACTUAL","INTERVENTIONAL",[75],"PHASE1","A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects",[78],"Healthy Volunteers",[80,81,82],"Phase 1","pharmacokinetics","safety","COMPLETED","2020-04-22",{"date":86,"type":72},"2020-04-24",{"date":88,"type":72},"2018-01-25",{"date":90,"type":72},"2018-04-16",{"name":5,"class":6},1]